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Clinical background
In the clinical setting, administration of organic nitrates
and nitric oxide (NO) donors has serious limitations such
as resistance to NO and organic nitrates due to insuffi-
cient biometabolism and development of tolerance fol-
lowing prolonged administration of NO soluble
guanylate cyclase (sGC) to NO [1,2]. This circumstance
has led to development of heme-dependent sGC stimula-
tors and heme-independent sGC activators. The sGC sti-
mulator riociguat and the sGC activator cinaciguat have
been shown to induce various beneficial effects in both
experimental and clinical research. Any direct dose-
dependent effects of these compounds on cell contrac-
tion and relaxation of isolated cardiac myocytes, however,
remain to be elucidated [3].
Methods and results
We analyzed the dose-dependent effects of the sGC sti-
mulator riociguat and the sGC activator cinaciguat at
clinical relevant concentrations (10-10–10-5 mol/L) on
contraction, relaxation, and calcium transients of iso-
lated field-stimulated cardiac myocytes from healthy
rats – in comparison to the b-adrenoreceptor agonist
isoproterenol (10-9–10-5 mol/l), the calcium channel
blocker verapamil (10-9–10-5 mol/L), and the cell perme-
able cGMP-analog 8-(4-Chlorophenylthio)-guanosine3’,5’-
cyclic monophosphate (8-pCPT-cGMP;10-9–10-6 mol/L).
Isoproterenol induced a dose-dependent significant
increase in cell contraction, contraction velocity, relaxation
velocity, and calcium transients, whereas verapamil
significantly decreased these parameters. On the other
hand, 8-pCPT-cGMP induced a negative inotropic effect
at 10-5mol/L accompanied by a slight increase in relaxa-
tion velocity. In contrast, neither riociguat nor cinaciguat
significantly influenced all measured parameters. Further-
more, we determined the immediate effect of riociguat
and cinaciguat on cGMP and cAMP production in iso-
lated rat cardiac myocytes. Whereas the cAMP signaling
cascade was influenced neither by riociguat nor by cinaci-
guat, both compounds (at 10-6 mol/L) significantly
increased intracellular cGMP generation. Moreover, this
accumulation was significantly augmented by cinaciguat in
the presence of the sGC inhibitor 1H- [1,2], 4 Oxadiazolo
[4,3-a]quinoxalin-1-one (ODQ, 25 µM) whereas ODQ
blocked cGMP generation by riociguat. However, blocking
of sGC did not influence cell contractility.
Conclusion
Our data revealed that an increase in cGMP levels
induced by riociguat and cinaciguat at clinical relevant
concentrations is not associated with acute direct effects
on cell contraction and relaxation in isolated cardiac
myocytes from healthy rats.
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